May 17, 2020

Glow's business model pays off in its app

2 min
Glow's business model pays off in its app.jpg
Written by Alyssa Clark The problem of infertility and trouble conceiving a child is not only troubling for the females who are taking prenatal vitami...

Written by Alyssa Clark


The problem of infertility and trouble conceiving a child is not only troubling for the females who are taking prenatal vitamins, exercising and eating the right foods, but the couples overall well-being is affected as well. The mHealth would wants to help those couples who seem plagued by the problem of infertility, by providing them with every resource possible in order to better their chances for a healthy conception.

Couples who are faced with the difficult problem of infertility or trouble conceiving can take refuge in knowing that a newly introduced app may hold some of the secrets in unlocking the path to conception. The App Store now holds the application entitled Glow which is an app proven to increase the chance of pregnancy. This company is so confident that they can get you pregnant, that they even offer to pay for infertility treatments if and when their system doesn’t work— confident to say the least. Glow is a program which is dependent upon the use of big data and the business sense of Pay Pal founder Max Levchin.

The idea for the Glow application came to its founders because they felt as if people who were trying to conceive did not have enough important information in order to know when their peak fertility was, and were becoming discouraged that they would never have children. Glow allows future parents and women more specifically, to track their period in order to understand their best windows for conception, and see if they need to be more active in their sex lives. The app is also useful because it can help future parents to stock up on ovulation kits and sending reminders to partners to avoid heat, in hopes of not killing any sperm.

Underneath the Glow First program, each couple spends $50 per month to use the app, and must try to conceive a child for at least 10 months while using the application. If using the program results in a pregnancy, then obviously the investment paid off. If not, the money from the community fund pays for infertility treatment. This business model is generating a wide-spread love of this product, and a renowned sense of community support.


About the Author

Alyssa Clark is the Editor of Healthcare Global

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article